Table 3.
Univariate analysis of prognostic factors for disease-free survival and overall survival in 132 patients with hepatocellular carcinoma
| Factor | n | 6-yr disease-free survival | P value | 6-yr overall survival | P value |
| NG2 | 0.000 | 0.000 | |||
| Negative | 84 | 15.2% | 29.2% | ||
| Positive | 48 | 6.7% | 9.5% | ||
| Age (yr) | 0.946 | 0.356 | |||
| ≥ 50 | 62 | 10.2% | 21.0% | ||
| < 50 | 70 | 9.7% | 31.4% | ||
| Sex | 0.281 | 0.316 | |||
| Male | 106 | 7.1% | 23.6% | ||
| Female | 26 | 21.7% | 38.5% | ||
| Tumor size | 0.122 | 0.116 | |||
| ≥ 5 cm | 90 | 11.8% | 28.9% | ||
| < 5 cm | 42 | 5.6% | 21.4% | ||
| TNM stage | 0.001 | 0.003 | |||
| I, II | 52 | 10.2% | 34.6% | ||
| III, IV | 80 | 9.7% | 21.3% | ||
| Differentiation | 0.108 | 0.119 | |||
| Well | 33 | 23.3% | 33.3% | ||
| Moderate | 52 | 2.0% | 9.6% | ||
| Poor | 47 | 9.5% | 12.8% | ||
| Serum AFP | 0.044 | 0.099 | |||
| ≥ 200 ng/dL | 42 | 2.3% | 18.0% | ||
| < 200 ng/dL | 90 | 13.6% | 14.0% | ||
| Invasion | 0.000 | 0.000 | |||
| Yes | 70 | 7.7% | 12.9% | ||
| No | 62 | 12.5% | 21.0% | ||
| Number | 0.041 | 0.057 | |||
| Multiple | 31 | 10.7% | 16.1% | ||
| Single | 101 | 9.7% | 16.8% | ||
| Capsule | 0.064 | 0.055 | |||
| Yes | 58 | 14.3% | 21.6% | ||
| No | 74 | 6.2% | 32.8% |
NG2: Neuron-glia antigen 2; TNM stage: Tumor node metastasis stage.